1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

  • July 2015
  • -
  • Roots Analysis Private Ltd.
  • -
  • 401 pages

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body’s own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). Interest has surged in other classes of immunotherapeutics; these include Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and many under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.

In addition to the marketed drugs (Yervoy, Opdivo and Keytruda), we expect a number of drugs currently in advanced stages of development (Tremelimumab, Elotuzumab, RG7446 and Avelumab)to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

The “Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025” report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic commercially available until other classes recently stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market.

In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future.

One of the key objectives of the study is to review the prospects laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise. Amongst other elements, the report elaborates upon the following key areas:
The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
Recent partnerships which have taken place over the last five years including product co-development, licensing and clinical trial collaborations
Combinationtherapies where Immune Checkpoint Inhibitors are being evaluated in combination with other anti-cancer agents/therapies
Various investments and grants received by the companies focused in this area
Competitive landscape and inherent threats to growth in the short and long term
Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2015. The rep

Table Of Contents

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Cancer Therapeutics and Immuno-Oncology
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining A Strong Foothold
3.3.1. Activation and Suppression Immunotherapies
3.4. Immuno-Oncology (Cancer Immunotherapy)
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Product Class Monoclonal Antibodies (mAbs) Cytokines Cell Based Therapies Immune Checkpoint Inhibitors

4. Current Market Landscape
4.1. Scope and Observations
4.2. Common Targets for Immune Checkpoint Inhibitors
4.3. Three Approved Immune Checkpoint Inhibitors in Market
4.4. Immune Checkpoint Inhibitors: Clinical and Preclinical Pipeline
4.4.1. Immune Checkpoint Inhibitors: Distribution by Drug Developers
4.4.2. Immune Checkpoint Inhibitors: Distribution by Targets
4.4.3. Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
4.4.4. Immune Checkpoint Inhibitors: Distribution by Type of Molecule
4.5. Overall Future Outlook: Sales Forecast, 2015 - 2025
4.5.1. Scope and Forecast Methodology
4.5.2. Overall Market Size and Forecast

5. CTLA-4 Inhibitors: Key Molecules and Future Outlook
5.1. CTLA-4 Inhibitors: Mechanism of Action
5.2. Pioneers of Immune Checkpoint Inhibitors Market
5.3. CTLA-4 Inhibitors: Pipeline Analysis
5.3.1. CTLA-4 Inhibitors: Distribution by Highest Phase of Development
5.3.2. CTLA-4 Inhibitors: Distribution by Type of Molecule

5.4. Yervoy / Ipilimumab (Bristol Myers Squibb)
5.4.1. Introduction
5.4.2. History of Development
5.4.3. Dosage and Manufacturing
5.4.4. Treatment Cost and Reimbursement
5.4.5. Current Status of Development
5.4.6. Key Clinical Trial Results
5.4.7. Historical Sales
5.4.8. Patent Expiry
5.4.9. Collaborations
5.4.10. Target Patient Population
5.4.11. Yervoy/ Ipilimumab Sales Forecast, 2015 - 2025

5.5. Tremelimumab (MedImmune)
5.5.1. Introduction
5.5.2. History of Development
5.5.3. Current Status of Development
5.5.4. Key Clinical Trial Results
5.5.5. Collaborations
5.5.6. Target Patient Population
5.5.7. Tremelimumab Sales Forecast, 2015 - 2025

5.6. CTLA-4 Inhibitors: Roots Analysis' Perspective

6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook
6.1. PD-1/PD-L1 Inhibitors: Mechanism of Action
6.2. Two Recent Launches Have Strengthened the Market Sentiment
6.3. PD-1 / PD-L1 Inhibitors: Pipeline Analysis
6.3.1. PD-1 / PD-L1 Inhibitors: Landscape Analysis
6.3.2. PD-1 / PD-L1 Inhibitors: Distribution by Target
6.3.3. PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
6.3.4. PD-1 / PD-L1 Inhibitors: Distribution by Type of Molecule

6.4. Opdivo/Nivolumab (Bristol Myers Squibb)
6.4.1. Introduction
6.4.2. History of Development
6.4.3. Dosage and Manufacturing
6.4.4. Treatment Cost and Reimbursement
6.4.5. Current Status of Development
6.4.6. Key Clinical Trial Results Metastatic Melanoma (Single Agent) NSCLC Advanced Melanoma (Combination Therapy) Hodgkin Lymphoma RCC Hepatocellular Carcinoma
6.4.7. Historical Sales
6.4.8. Patent Expiry
6.4.9. Collaborations
6.4.10. Target Patient Population
6.4.11. Opdivo /Nivolumab Sales Forecast, 2015 - 2025

6.5. Keytruda / Pembrolizumab (Merck)
6.5.1. Introduction
6.5.2. History of Development
6.5.3. Dosage and Manufacturing
6.5.4. Treatment Cost and Reimbursement
6.5.5. Current Status of Development
6.5.6. Key Clinical Trial Results Advanced Melanoma NSCLC Advanced Solid Tumors Hodgkin Lymphoma Advanced Head and Neck Can

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Related Market Segments :

Lung Cancer


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.